Clinical Trials
Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
Sponsor: National Heart, Lung, and Blood Institute
Enrollment: Completed in January 2011
Eligibility: Patients with Marfan syndrome between age 6 months and 25 years with a dilated aorta who have not had previous aortic surgery
Aim: To compare the effects of atenolol to those of losartan on the rate of aortic growth and progression of aortic regurgitation in patients with Marfan syndrome
Website: http://www.pediatricheartnetwork.com/marfan.asp
Additional Information
Tejani Mendiz-Ramdeen
Tel: (212) 241-6012
E-mail: tejani.mendiz-ramdeen@mssm.edu
Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) is an observational study to identify common genetic causes of congenital heart disease and genetic modifiers.
Sponsor: National Heart, Lung, and Blood Institute
Enrollment: Slated to run through October 2015 (possibly longer, if funding extended).
Eligibility: Individuals of all ages with congenital heart disease (CHD).Information about the medical history of the person with CHD and family members will be collected, along with DNA from the study participant, the participant's parents, and family members of interest.
Aim: To study relationships between genetic factors and the characteristics and clinical outcomes in patients with congenital heart defects (CHD). The study does not provide treatment for the CHD.
Website: http://www.benchtobassinet.com/PCGCresearch.asp
Additional Information
Tejani Mendiz-Ramdeen
Tel: (212) 241-6012
E-mail: tejani.mendiz-ramdeen@mssm.edu